Key points are not available for this paper at this time.
We need a paradigm shift towards prevention-based risk governance of chemicals and advanced materials via a transition towards SSbD. Defining SSbD metrics and trade-offs should be a co-creative process and can benefit from applying digital tools.
Hristozov et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: